Advanced triple-negative breast cancer (TNBC), Advanced HR[+]/HER2[–] breast cancer. research hub

Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative or Luminal Breast Cancer. – The PRIMED Study –

This study, called PRIMED, is looking at ways to make a breast cancer medicine called Trodelvy easier to tolerate. It's for people with advanced triple-negative or HR+/HER2- breast cancer, focusing on reducing side effects like severe diarrhoea and low white blood cell counts.